We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current MYGN market cap is 1.38B. The company's latest EPS is USD -2.8991 and P/E is -5.24.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 183.5M | 191.9M | 196.6M | 202.2M | 211.5M |
Operating Income | -113.7M | -60.1M | -31.4M | -27.9M | -25.7M |
Net Income | -116.1M | -61.3M | -31.2M | -26M | -36.7M |
Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 641.4M | 299.8M | 690.6M | 678.4M | 753.2M |
Operating Income | -231.7M | -87.8M | -190.5M | -140.6M | -257.4M |
Net Income | -199.5M | -53.1M | -27.2M | -112M | -263.3M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.19B | 1.15B | 1.15B | 1.11B | 1.09B |
Total Liabilities | 452M | 465.7M | 363.3M | 350.5M | 344.6M |
Total Equity | 735.2M | 683.4M | 783.2M | 760M | 740.5M |
Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.4B | 1.42B | 1.32B | 1.2B | 1.15B |
Total Liabilities | 486.4M | 537.8M | 352.9M | 312.9M | 363.3M |
Total Equity | 918.2M | 881M | 967.8M | 885.8M | 783.2M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -34.1M | -56.2M | -110.9M | -18.6M | -16M |
Investing | 46.4M | 43.9M | 31.9M | -7.1M | -13.5M |
Financing | 33.5M | 31M | 152.9M | -8.8M | -6.4M |
Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 60.7M | -73.7M | 18.2M | -106.3M | -110.9M |
Investing | 19.3M | 28M | 274.4M | -77.5M | 31.9M |
Financing | -10M | -2.1M | -150.6M | -8M | 152.9M |
Market Cap | 1.38B |
Price to Earnings Ratio | -5.24 |
Price to Sales Ratio | 1.83 |
Price to Cash Ratio | 10.45 |
Price to Book Ratio | 1.76 |
Dividend Yield | - |
Shares Outstanding | 90.82M |
Average Volume (1 week) | 1.1M |
Average Volume (1 Month) | 980.84k |
52 Week Change | -15.44% |
52 Week High | 29.30 |
52 Week Low | 15.18 |
Spread (Intraday) | 1.85 (11.46%) |
Company Name | Myriad Genetics Inc |
Address |
corporation trust center wilmington, delaware 19801 |
Website | https://www.myriad.com |
Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions